Hong Nyun Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hong Nyun Kim has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Dong Heon Yang
Division of Cardiology, Department of Internal Medicine, Kyungpook National University, Daegu, Korea
11 shared publications - Bo Eun Park
Kyungpook National University Hospital
10 shared publications - Jang Hoon Lee
Department of Internal Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea
9 shared publications - Myung Hwan Bae
Division of Cardiology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea
9 shared publications - Yongkeun Cho
Division of Cardiology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea
9 shared publications - Hun Sik Park
Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea
8 shared publications
Latest Publications
- Open Access
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e045151
Long‐Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS
Background: Intravascular ultrasound (IVUS)‐guided percutaneous coronary intervention improves patient outcomes, yet the impact of a center's IVUS experience on long‐term outcomes remains unclear. We evaluated whether the prognostic association of IVUS‐guided percutaneous coronary intervention in patients with acute myocardial infarction differs based on a center's level of IVUS use. Methods: We retrospectively analyzed 9752 patients with acute myocardial infarction treated with second‐generation drug‐eluting stents from the KAMIR‐NIH (Korean Acute Myocardial Infarction Registry–National Institutes of Health). The primary outcome was 3‐year major adverse cardiovascular events, defined as a composite of all‐cause death, myocardial infarction, and coronary revascularization. The secondary outcome was target‐lesion failure, defined as a composite of cardiac death, target‐vessel myocardial infarction, and ischemia‐driven target lesion revascularization. Centers were classified into higher‐ or lower‐IVUS‐use groups on the basis of median institutional usage (10.3%). Results: In higher‐use centers, IVUS‐guided percutaneous coronary intervention was associated with lower rates of major adverse cardiovascular events (15.3% versus 18.5%, P =0.016) and target‐lesion failure (6.3% versus 8.3%, P =0.039) in propensity score–matched populations. Multivariate Cox analysis confirmed lower risks of major adverse cardiovascular events (hazard ratio [HR], 0.80 [95% CI, 0.69–0.93]; P =0.003) and target‐lesion failure (HR, 0.75 [95% CI, 0.59–0.93]; P =0.01). Conversely, in lower‐use centers, IVUS guidance was not associated with significant differences in major adverse cardiovascular events (15.7% versus 18.6%, P =0.422) or target‐lesion failure (8.9% versus 10.4%, P =0.644). Conclusions: The association of IVUS‐guided percutaneous coronary intervention with lower adverse event rates was more apparent and statistically demonstrable in centers with higher IVUS use. These findings suggest that institutional experience may amplify the observable impact of IVUS guidance, underscoring the potential value of standardized IVUS implementation in acute myocardial infarction management.
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e045151
Open AccessLong‐Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS
Background: Intravascular ultrasound (IVUS)‐guided percutaneous coronary intervention improves patient outcomes, yet the impact of a center's IVUS experience on long‐term outcomes remains unclear. We evaluated whether the prognostic association of IVUS‐guided percutaneous coronary intervention in patients with acute myocardial infarction differs based on a center's level of IVUS use. Methods: We retrospectively analyzed 9752 patients with acute myocardial infarction treated with second‐generation drug‐eluting stents from the KAMIR‐NIH (Korean Acute Myocardial Infarction Registry–National Institutes of Health). The primary outcome was 3‐year major adverse cardiovascular events, defined as a composite of all‐cause death, myocardial infarction, and coronary revascularization. The secondary outcome was target‐lesion failure, defined as a composite of cardiac death, target‐vessel myocardial infarction, and ischemia‐driven target lesion revascularization. Centers were classified into higher‐ or lower‐IVUS‐use groups on the basis of median institutional usage (10.3%). Results: In higher‐use centers, IVUS‐guided percutaneous coronary intervention was associated with lower rates of major adverse cardiovascular events (15.3% versus 18.5%, P =0.016) and target‐lesion failure (6.3% versus 8.3%, P =0.039) in propensity score–matched populations. Multivariate Cox analysis confirmed lower risks of major adverse cardiovascular events (hazard ratio [HR], 0.80 [95% CI, 0.69–0.93]; P =0.003) and target‐lesion failure (HR, 0.75 [95% CI, 0.59–0.93]; P =0.01). Conversely, in lower‐use centers, IVUS guidance was not associated with significant differences in major adverse cardiovascular events (15.7% versus 18.6%, P =0.422) or target‐lesion failure (8.9% versus 10.4%, P =0.644). Conclusions: The association of IVUS‐guided percutaneous coronary intervention with lower adverse event rates was more apparent and statistically demonstrable in centers with higher IVUS use. These findings suggest that institutional experience may amplify the observable impact of IVUS guidance, underscoring the potential value of standardized IVUS implementation in acute myocardial infarction management.
- Open Access
- 21 July 2023
- Published by Wiley in Clinical Case Reports
- Vol. 11 (7) , e7597
Acute decompensated heart failure after transcatheter aortic valve implantation: A case report
Key Clinical Message: Transcatheter aortic valve implantation (TVAI) is a widely used treatment modality for severe aortic stenosis. The complication rates of the procedure have gradually decreased over time, owing to the improvements in procedural skills and development of TVAI devices. However, several rare but serious complications can still occur after TAVI. We recently encountered acute decompensated heart failure as a rare and fatal complication of TAVI and would like to share our experience.
- 21 July 2023
- Published by Wiley in Clinical Case Reports
- Vol. 11 (7) , e7597
Open AccessAcute decompensated heart failure after transcatheter aortic valve implantation: A case report
Key Clinical Message: Transcatheter aortic valve implantation (TVAI) is a widely used treatment modality for severe aortic stenosis. The complication rates of the procedure have gradually decreased over time, owing to the improvements in procedural skills and development of TVAI devices. However, several rare but serious complications can still occur after TAVI. We recently encountered acute decompensated heart failure as a rare and fatal complication of TAVI and would like to share our experience.
- Open Access
- 10 January 2023
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 28 (2) , e13036
Predictors of stroke or systemic embolism in patients with non‐valvular atrial fibrillation with CHA2DS2‐VASc score of 0
Background: Anticoagulant therapy has been important for stroke prevention in patients with atrial fibrillation (AF). However, it was not recommended due to its relatively higher risk of bleeding than its lower risk of stroke in patients with a CHA2DS2‐VASc score of 0.Hypothesis: This study aimed to evaluate the predictors of stroke in AF patients with very low risk of stroke.Methods: Between 1990 and 2020, 542 patients with non‐valvular AF (NVAF) with a CHA2DS2‐VASc score of 0 followed up for at least 6 months were enrolled. Patients with only being woman as a risk factor were included as a CHA2DS2‐VASc score of 0 in this study. The primary outcome was stroke or systemic embolism.Results: The primary outcome rate was 0.78%/year. In Cox hazard model, age of ≥50 years at diagnosis (hazard ratio [HR] 6.710, 95% confidence interval [CI] 1.811–24.860, p = .004), LVEDD of ≥46 mm (HR 4.513, 95% CI 1.038–19.626, p = .045), and non‐paroxysmal AF (HR 5.575, 95% CI 1.621–19.175, p = .006) were identified as independent predictors of stroke or systemic embolism. Patients with all three independent predictors had a higher risk of stroke or systemic embolism (4.21%/year), whereas those without did not have a stroke or systemic embolism.Conclusion: The annual stroke or systemic embolism rate in NVAF patients with CHA2DS2‐VASc score of 0 was 0.78%/year, and age at AF diagnosis, LVEDD, and non‐paroxysmal AF were independent predictors of stroke or systemic embolism in patients considered to have a very low risk of stroke.
- 10 January 2023
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 28 (2) , e13036
Open AccessPredictors of stroke or systemic embolism in patients with non‐valvular atrial fibrillation with CHA2DS2‐VASc score of 0
Background: Anticoagulant therapy has been important for stroke prevention in patients with atrial fibrillation (AF). However, it was not recommended due to its relatively higher risk of bleeding than its lower risk of stroke in patients with a CHA2DS2‐VASc score of 0.Hypothesis: This study aimed to evaluate the predictors of stroke in AF patients with very low risk of stroke.Methods: Between 1990 and 2020, 542 patients with non‐valvular AF (NVAF) with a CHA2DS2‐VASc score of 0 followed up for at least 6 months were enrolled. Patients with only being woman as a risk factor were included as a CHA2DS2‐VASc score of 0 in this study. The primary outcome was stroke or systemic embolism.Results: The primary outcome rate was 0.78%/year. In Cox hazard model, age of ≥50 years at diagnosis (hazard ratio [HR] 6.710, 95% confidence interval [CI] 1.811–24.860, p = .004), LVEDD of ≥46 mm (HR 4.513, 95% CI 1.038–19.626, p = .045), and non‐paroxysmal AF (HR 5.575, 95% CI 1.621–19.175, p = .006) were identified as independent predictors of stroke or systemic embolism. Patients with all three independent predictors had a higher risk of stroke or systemic embolism (4.21%/year), whereas those without did not have a stroke or systemic embolism.Conclusion: The annual stroke or systemic embolism rate in NVAF patients with CHA2DS2‐VASc score of 0 was 0.78%/year, and age at AF diagnosis, LVEDD, and non‐paroxysmal AF were independent predictors of stroke or systemic embolism in patients considered to have a very low risk of stroke.
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (46) , e399
Impact of Positron Emission Tomography Viability Imaging: Guided Revascularizations on Clinical Outcomes in Patients With Myocardial Scar on Single-Photon Emission Computed Tomography Scans
Park JS, et al. J Korean Med Sci. 2023 Nov;38:e399. https://doi.org/10.3346/jkms.2023.38.e399
- 1 January 2023
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (46) , e399
Open AccessImpact of Positron Emission Tomography Viability Imaging: Guided Revascularizations on Clinical Outcomes in Patients With Myocardial Scar on Single-Photon Emission Computed Tomography Scans
Park JS, et al. J Korean Med Sci. 2023 Nov;38:e399. https://doi.org/10.3346/jkms.2023.38.e399
- Open Access
- 26 December 2022
- Published by Wiley
Acute Decompensated Heart Failure after Transcatheter Aortic Valve Implantation: A Case Report
Transcatheter aortic valve implantation (TVAI) is a widely used treatment for aortic stenosis. The complication rates of TAVI have decreased over time, owing to the improvements in procedural skills.We encountered acute decompensated heart failure cause by stress induced cardiomyopathy or ventricular stunning as a rare and fatal complication of TAVI.
- 26 December 2022
- Published by Wiley
Open AccessAcute Decompensated Heart Failure after Transcatheter Aortic Valve Implantation: A Case Report
Transcatheter aortic valve implantation (TVAI) is a widely used treatment for aortic stenosis. The complication rates of TAVI have decreased over time, owing to the improvements in procedural skills.We encountered acute decompensated heart failure cause by stress induced cardiomyopathy or ventricular stunning as a rare and fatal complication of TAVI.
- Open Access
- 1 January 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (21) , e167
Impact of the COVID-19 Pandemic on Patient Delay and Clinical Outcomes for Patients With Acute Myocardial Infarction
Choi H, et al. J Korean Med Sci. 2022 May;37(21):e167. https://doi.org/10.3346/jkms.2022.37.e167
- 1 January 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (21) , e167
Open AccessImpact of the COVID-19 Pandemic on Patient Delay and Clinical Outcomes for Patients With Acute Myocardial Infarction
Choi H, et al. J Korean Med Sci. 2022 May;37(21):e167. https://doi.org/10.3346/jkms.2022.37.e167
- Open Access
- 31 October 2021
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 38 (4) , 337-343
Prognostic impact of chromogranin A in patients with acute heart failure
Background: Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure.Methods: We retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization.Results: In-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors.Conclusion: The prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients.
- 31 October 2021
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 38 (4) , 337-343
Open AccessPrognostic impact of chromogranin A in patients with acute heart failure
Background: Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure.Methods: We retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization.Results: In-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors.Conclusion: The prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients.
- Open Access
- 23 October 2021
- Published by Wiley in Clinical Case Reports
- Vol. 9 (10) , e04268
A case of paroxysmal complete atrioventricular block in a COVID‐19 patient
Many types of cardiac arrhythmias can occur in people with COVID‐19, and these arrhythmias can affect the patient's outcomes. We have experienced paroxysmal complete atrioventricular block in a patient with COVID‐19 and would like to share the course of treatment.
- 23 October 2021
- Published by Wiley in Clinical Case Reports
- Vol. 9 (10) , e04268
Open AccessA case of paroxysmal complete atrioventricular block in a COVID‐19 patient
Many types of cardiac arrhythmias can occur in people with COVID‐19, and these arrhythmias can affect the patient's outcomes. We have experienced paroxysmal complete atrioventricular block in a patient with COVID‐19 and would like to share the course of treatment.
- Open Access
- 13 February 2021
- Published by Wiley
A Case of Paroxysmal Complete Atrioventricular Block in a COVID-19 Patient
A patient with coronavirus disease 2019 showed complete atrioventricular block on electrocardiogram. The patient was undergoing mechanical ventilator treatment for severe hypoxia. Intrathoracic pressure was reduced by adjusting the tidal volume and the positive end-expiratory pressure of the mechanical ventilator. After that, complete atrioventricular block didn't occur during the hospitalization.
- 13 February 2021
- Published by Wiley
Open AccessA Case of Paroxysmal Complete Atrioventricular Block in a COVID-19 Patient
A patient with coronavirus disease 2019 showed complete atrioventricular block on electrocardiogram. The patient was undergoing mechanical ventilator treatment for severe hypoxia. Intrathoracic pressure was reduced by adjusting the tidal volume and the positive end-expiratory pressure of the mechanical ventilator. After that, complete atrioventricular block didn't occur during the hospitalization.
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (2) , e15
Impact of Cardiovascular Risk Factors and Cardiovascular Diseases on Outcomes in Patients Hospitalized with COVID-19 in Daegu Metropolitan City
Park BE, et al. J Korean Med Sci. 2020 Oct;36(2):e15. https://doi.org/10.3346/jkms.2021.36.e15
- 1 January 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (2) , e15
Open AccessImpact of Cardiovascular Risk Factors and Cardiovascular Diseases on Outcomes in Patients Hospitalized with COVID-19 in Daegu Metropolitan City
Park BE, et al. J Korean Med Sci. 2020 Oct;36(2):e15. https://doi.org/10.3346/jkms.2021.36.e15